Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients

International Journal of Cancer

Volumn 105, Issue 4, 2003, Pages 491-493

  Nakayama, Hiroshi ^a   Hibi, Kenji ^a   Takase, Tsunenobu ^a   Yamazaki, Taiji ^a   Kasai, Yasushi ^a   Ito, Katsuki ^a   Akiyama, Seiji ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Methylation; P16

Indexed keywords

PROTEIN P16;

ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; COLORECTAL CANCER; CPG ISLAND; EARLY DIAGNOSIS; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METHYLATION; MOLECULAR GENETICS; MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR GROWTH;

COLORECTAL NEOPLASMS; DNA; DNA METHYLATION; GENES, P16; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS (GENETICS);

EID: 0038662810     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11117     Document Type: Article

References (17)

1. Parkin DM, Laara E, Muir C.S. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1998;41:184-97.
2. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-22.
3. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1997;46:646-50.
4. Hibi K, Robinson CR, Booker S, Wu L, Hamilton SR, Sidransky D, Jen J. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998;58:1405-7.
5. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
6. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4531-5.
7. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000;60:1835-9.
8. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
9. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59:71-3.
10. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
11. Nakayama H, Hibi K, Taguchi M, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 2002;188:115-9.
12. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135-8.
13. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992;89:1827-31.
14. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994;22:2990-7.
15. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
16. Hibi K, Nakayama H, Koike M, Kasai Y, Ito K, Akiyama S, Nakao A. Colorectal cancers with both p16 and p14 methylation show invasive characteristics. Jpn J Cancer Res 2002;93:883-7.
17. Esteller M, Gonzalez S, Risques RA, Marcuello E, Mangues R, Germa JR, Herman JG, Capella G, Peinado MA. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304.